Entest Group Inc

[sizzleweed]

Massive news Jack. Christine Ichim is taking us to the promised land. Released today on Market wire. GLTA ENTB

Proof-of-concept studies originally identifying NR2F6 as a target for cancer stem cells were performed by Dr. Christine Ichim, senior research consultant with Regen Biopharma, along with scientists at the University of Toronto. These studies showed that silencing of the NR2F6 gene in leukemia cells led to the cells losing their leukemic characteristics. This finding was the subject of a US patent application "Modulation of NR2F6 and methods and uses thereof" which was assigned to Regen BioPharma. The data was subsequently published in the peer-reviewed journal Leukemia1.